Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody
Identifieur interne : 000437 ( Main/Exploration ); précédent : 000436; suivant : 000438Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody
Auteurs : RBID : ISTEX:259_1990_Article_BF01268019.pdfEnglish descriptors
- KwdEn :
Abstract
The study was undertaken to define the potential use of indium 111 carcinoembryonic antigen-specific antibody labelled [CEA F(ab′)2] for the radioimmunodetection of colorectal carcinoma using an intraoperative hand-held gamma probe. The use of a linear radioactive source allowed optimization of physical characteristics. The best results regarding sensitivity and resolution were obtained using a 5-mm thick tungsten alloy collimator. A simulation study with a liver phantom (22 MBq or 0.6 mCi) was performed to determine the effect of side scatter as opposed to direct background and showed that it is possible to detect small radioactive targets (3.7 KBq or 0.1 μCi) 4 cm from the phantom. A clinical study performed with ten patients showed that tumours with good uptake of CEA-specific antibody could be detected with sufficient contrast in two patients when the probe was used. Results of a biodistribution study performed after tumour fragment or normal tissue countings in a well counter showed high tumour uptake (above 8 x 10−3 injected dose/g) and tumour-to-normal tissue ratios (between 2.5 and 20) in five patients. Results with the probe showed markedly lower ratios. There was no correlation between absolute tumour uptake and the count rates of tumour measured intraoperatively. This can be attributed to the degradation of depth resolution resulting from the high energy photopeak of gamma-emitting111In.
DOI: 10.1007/BF01268019
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title>Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody</title><author><name>C. Curtet</name><affiliation wicri:level="1"><mods:affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex</wicri:regionArea><wicri:noRegion>Cédex</wicri:noRegion><wicri:noRegion>Cédex</wicri:noRegion></affiliation></author><author><name>J. P. Vuillez</name><affiliation wicri:level="1"><mods:affiliation>Service de Médecine Nucléaire, Centre Hospitalier Universitaire, Grenoble, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Médecine Nucléaire, Centre Hospitalier Universitaire, Grenoble</wicri:regionArea><placeName><region type="région">Rhône-Alpes</region><settlement type="city">Grenoble</settlement></placeName></affiliation></author><author><name>G. Daniela</name><affiliation wicri:level="1"><mods:affiliation>Service Applications des Radioélements, DAMRI, CEA, Saclay, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service Applications des Radioélements, DAMRI, CEA, Saclay</wicri:regionArea><wicri:noRegion>Saclay</wicri:noRegion><wicri:noRegion>Saclay</wicri:noRegion></affiliation></author><author><name>G. Aillet</name><affiliation wicri:level="1"><mods:affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex</wicri:regionArea><wicri:noRegion>Cédex</wicri:noRegion><wicri:noRegion>Cédex</wicri:noRegion></affiliation></author><author><name>A. Chetanneau</name><affiliation wicri:level="1"><mods:affiliation>Service de Médecine Nucléaire, Centre R. Gauducheau, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Médecine Nucléaire, Centre R. Gauducheau, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>J. Visset</name><affiliation wicri:level="1"><mods:affiliation>Service de Chirurgie Oncologique, Centre Hospitalier Universitaire, Nantes, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Service de Chirurgie Oncologique, Centre Hospitalier Universitaire, Nantes</wicri:regionArea><placeName><region type="région">Pays de la Loire</region><settlement type="city">Nantes</settlement></placeName></affiliation></author><author><name>M. Kremer</name><affiliation wicri:level="1"><mods:affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex</wicri:regionArea><wicri:noRegion>Cédex</wicri:noRegion><wicri:noRegion>Cédex</wicri:noRegion></affiliation></author><author><name>P. Thédrez</name><affiliation wicri:level="1"><mods:affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex</wicri:regionArea><wicri:noRegion>Cédex</wicri:noRegion><wicri:noRegion>Cédex</wicri:noRegion></affiliation></author><author><name>J. F. Chatal</name><affiliation wicri:level="1"><mods:affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</mods:affiliation><country xml:lang="fr">France</country><wicri:regionArea>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex</wicri:regionArea><wicri:noRegion>Cédex</wicri:noRegion><wicri:noRegion>Cédex</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="RBID">ISTEX:259_1990_Article_BF01268019.pdf</idno><date when="1990">1990</date><idno type="doi">10.1007/BF01268019</idno><idno type="wicri:Area/Main/Corpus">000306</idno><idno type="wicri:Area/Main/Curation">000306</idno><idno type="wicri:Area/Main/Exploration">000437</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Colorectal carcinoma</term><term>Hand-held gamma probe</term><term>Radioimmunoguided surgery</term><term>Radiolabelled monoclonal antibodies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="eng">The study was undertaken to define the potential use of indium 111 carcinoembryonic antigen-specific antibody labelled [CEA F(ab′)2] for the radioimmunodetection of colorectal carcinoma using an intraoperative hand-held gamma probe. The use of a linear radioactive source allowed optimization of physical characteristics. The best results regarding sensitivity and resolution were obtained using a 5-mm thick tungsten alloy collimator. A simulation study with a liver phantom (22 MBq or 0.6 mCi) was performed to determine the effect of side scatter as opposed to direct background and showed that it is possible to detect small radioactive targets (3.7 KBq or 0.1 μCi) 4 cm from the phantom. A clinical study performed with ten patients showed that tumours with good uptake of CEA-specific antibody could be detected with sufficient contrast in two patients when the probe was used. Results of a biodistribution study performed after tumour fragment or normal tissue countings in a well counter showed high tumour uptake (above 8 x 10−3 injected dose/g) and tumour-to-normal tissue ratios (between 2.5 and 20) in five patients. Results with the probe showed markedly lower ratios. There was no correlation between absolute tumour uptake and the count rates of tumour measured intraoperatively. This can be attributed to the degradation of depth resolution resulting from the high energy photopeak of gamma-emitting111In.</div></front></TEI><mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="347d459f0dd41b9c918d1dff20748c879d1f24d9"><titleInfo lang="eng"><title>Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody</title></titleInfo><name type="personal"><namePart type="given">C.</namePart><namePart type="family">Curtet</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</affiliation></name><name type="personal"><namePart type="given">J. P.</namePart><namePart type="family">Vuillez</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service de Médecine Nucléaire, Centre Hospitalier Universitaire, Grenoble, France</affiliation></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Daniela</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service Applications des Radioélements, DAMRI, CEA, Saclay, France</affiliation></name><name type="personal"><namePart type="given">G.</namePart><namePart type="family">Aillet</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</affiliation></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">Chetanneau</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service de Médecine Nucléaire, Centre R. Gauducheau, Nantes, France</affiliation></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">Visset</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>Service de Chirurgie Oncologique, Centre Hospitalier Universitaire, Nantes, France</affiliation></name><name type="personal"><namePart type="given">M.</namePart><namePart type="family">Kremer</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</affiliation></name><name type="personal"><namePart type="given">P.</namePart><namePart type="family">Thédrez</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</affiliation></name><name type="personal"><namePart type="given">J. F.</namePart><namePart type="family">Chatal</namePart><role><roleTerm type="text">author</roleTerm></role><affiliation>INSERM U.211, Faculté de Médecine, 1, rue Gaston Veil, F-44035, Nantes, Cédex, France</affiliation></name><typeOfResource>text</typeOfResource><genre>Original article</genre><genre>Original Paper</genre><originInfo><publisher>Springer-Verlag, Berlin/Heidelberg</publisher><dateValid encoding="w3cdtf">2004-12-19</dateValid><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="eng">The study was undertaken to define the potential use of indium 111 carcinoembryonic antigen-specific antibody labelled [CEA F(ab′)2] for the radioimmunodetection of colorectal carcinoma using an intraoperative hand-held gamma probe. The use of a linear radioactive source allowed optimization of physical characteristics. The best results regarding sensitivity and resolution were obtained using a 5-mm thick tungsten alloy collimator. A simulation study with a liver phantom (22 MBq or 0.6 mCi) was performed to determine the effect of side scatter as opposed to direct background and showed that it is possible to detect small radioactive targets (3.7 KBq or 0.1 μCi) 4 cm from the phantom. A clinical study performed with ten patients showed that tumours with good uptake of CEA-specific antibody could be detected with sufficient contrast in two patients when the probe was used. Results of a biodistribution study performed after tumour fragment or normal tissue countings in a well counter showed high tumour uptake (above 8 x 10−3 injected dose/g) and tumour-to-normal tissue ratios (between 2.5 and 20) in five patients. Results with the probe showed markedly lower ratios. There was no correlation between absolute tumour uptake and the count rates of tumour measured intraoperatively. This can be attributed to the degradation of depth resolution resulting from the high energy photopeak of gamma-emitting111In.</abstract><subject lang="eng"><genre>Key words</genre><topic>Radioimmunoguided surgery</topic><topic>Hand-held gamma probe</topic><topic>Radiolabelled monoclonal antibodies</topic><topic>Colorectal carcinoma</topic></subject><relatedItem type="series"><titleInfo type="abbreviated"><title>Eur J Nucl Med</title></titleInfo><titleInfo><title>European Journal of Nuclear Medicine</title><partNumber>Year: 1990</partNumber><partNumber>Volume: 17</partNumber><partNumber>Number: 6-8</partNumber></titleInfo><genre>Archive Journal</genre><originInfo><dateIssued encoding="w3cdtf">1990-06-01</dateIssued><copyrightDate encoding="w3cdtf">1990</copyrightDate></originInfo><subject usage="primary"><topic>Medicine & Public Health</topic><topic>Imaging / Radiology</topic><topic>Nuclear Medicine</topic></subject><identifier type="issn">0340-6997</identifier><identifier type="issn">Electronic: 1619-7089</identifier><identifier type="matrixNumber">259</identifier><identifier type="local">IssueArticleCount: 18</identifier><recordInfo><recordOrigin>Springer-Verlag, 1990</recordOrigin></recordInfo></relatedItem><identifier type="doi">10.1007/BF01268019</identifier><identifier type="matrixNumber">Art3</identifier><identifier type="local">BF01268019</identifier><accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition><accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition><accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition><accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition><accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition><accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition><part><extent unit="pages"><start>299</start><end>304</end></extent></part><recordInfo><recordOrigin>Springer-Verlag, 1990</recordOrigin><recordIdentifier>259_1990_Article_BF01268019.pdf</recordIdentifier></recordInfo></mods></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000437 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000437 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:259_1990_Article_BF01268019.pdf
|texte= Feasibility study of radioimmunoguided surgery of colorectal carcinomas using indium-111 CEA-specific monoclonal antibody
}}
| This area was generated with Dilib version V0.5.81. |  |